Abstract
Abstract
Background
Primary small cell carcinoma of the pancreas (SCCP) is a rare malignant neuroendocrine carcinoma (NEC). Typically, it presents with lymphovascular invasion as well as metastasis at the time of diagnosis which portends a dismal prognosis. Treatment is typically based on therapy used for other aggressive NECs such as small cell lung cancer. Although multimodal surgery, radiation and chemotherapy may improve prognosis, the outcome generally remains poor.
Case presentation
Here we present a primary SCCP managed with neoadjuvant multi-agent chemotherapy combined with radiotherapy and surgery
Conclusions
Multi-disciplinary therapy resulted in an ongoing 28 + month radiographic complete response and overall survival.
Funder
National Cancer Institute
National Center for Advancing Translational Sciences
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference20 articles.
1. Nagtegaal ID, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–8.
2. Botta GP, Bhangoo MS, Sigal D. Influence of organ location and sex of patient on pancreatic neuroendocrine tumor 5-year survival. J Clin Oncol. 2017;35:e15713–e15713.
3. Dasari A, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.
4. Basturk O, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39:683–90.
5. Bukhari MH, Niazi S, Shah N, Anwar M, Khalee M, Samina Q, Munir M. Histological diagnosis and frequency of primary endocrine tumors (ETs) and neuroendocrine tumors (NETs) according to WHO classification. Int J Endocrinol Metab. 2008;6:205–14.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献